Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736579 · ClinicalTrials.gov registry record · Phase 3
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT01736579 is a Phase 3 study that was terminated before completion, run by Baxalta now part of Shire. The registered enrollment target is 6 participants.
The verdict
NCT01736579, a Phase 3 study, was terminated before completion, sponsored by Baxalta now part of Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701. Participants and investigators will be blinded to dose unless otherwise notified by the sponsor.
Interventions
- DRUG Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-11-29 |
| Est. Completion | 2013-06-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736579
The ClinicalTrials.gov registry entry for NCT01736579 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immune Globulin Intravenous (Human), 10% (IGIV, 10%) is the first listed.
NCT01736579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736579 about?
NCT01736579 is a clinical study titled "Long-Term Study of IGIV, 10% in Alzheimer´s Disease". The purpose of this long-term study is to provide additional evidence of safety and efficacy of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase 3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg or 0.4 g/kg body weigh...
What is the current status of trial NCT01736579?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2012-11-29. Estimated completion is 2013-06-04.
What interventions are being tested in trial NCT01736579?
The interventions under investigation include: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) (DRUG).
Who is sponsoring clinical trial NCT01736579?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.